Yesterday, Bitcoin attempted to make a new ATH but encountered limit selling activity, after which it declined to the nearest buyer zone. Currently, we've received an initial buyer reaction in the form of a cluster anomaly in the mentioned zone, but there is no market buyer yet. The priority scenario is the development of a weak buying wave up to the nearest resistance zones, from where sales will follow. If a strong buyer emerges during the selling wave who will defend their positions, then a full breakout of ATH will be possible, but for now, we should expect a decline. Selling zones: ~$105,000(pushing volume), $107,000-$109,000(volume anomalies). Buying zones: $102,000-$99,600(volume zone), $97,400-$96,300(volume zone), $92,400-94,300(volume anomalies), $90,600-$86,300(accumulated volumes). Interesting altcoins For the 1000CHEEMSUSDT futures pair, we have reached the selling zone, from where we should expect a correction if there is a reaction. https://www.tradingview.com/x/MvKUHrDR/
A bearish move is forming based on the ICT pattern.
Hey guys we just hit take profit and if you executed with me congrats tho this trade was from our last week analysis but it played out perfectly patience does pays and follow me up for more A+ setup and also this trade has covered our loss from our first trade of the year and more I will update you guys if I want to get into another trade and incase you miss out check out my page and see the before of this trade now when the trade hit take profit…Enjoy
?Hi! Hola! Ola! Bonjour! Hallo!? Dear Money Makers & Robbers, ? ? Based on ?Thief Trading style technical and fundamental analysis?, here is our master plan to heist the EUR/USD "The Fibre" Forex market. Please adhere to the strategy I've outlined in the chart, which emphasizes long entry. Our aim is the high-risk Red Zone. Risky level, overbought market, consolidation, trend reversal, trap at the level where traders and bearish robbers are stronger. Be wealthy and safe trade.??? Entry ? : Traders & Thieves with New Entry A bull trade can be initiated on the MA level breakout of 1.04400 Stop Loss ?: Using the 3H period, the recent / nearest low or high level. Goal ?: 1.06000 (or) Escape Before the Target Scalpers, take note ? : only scalp on the Long side. If you have a lot of money, you can go straight away; if not, you can join swing traders and carry out the robbery plan. Use trailing SL to safeguard your money ?. Fundamental Outlook ??️ Here are some neutral factors that could impact the EUR/USD pair: EU-US Trade Talks: The ongoing trade talks between the EU and US could lead to a neutral outcome, with both sides agreeing to maintain current trade relationships without making significant changes. European Central Bank (ECB) Forward Guidance: The ECB's forward guidance on interest rates and monetary policy could remain unchanged, providing no clear direction for the EUR/USD pair. US Federal Reserve (Fed) Balance Sheet: The Fed's balance sheet reduction could continue at a steady pace, having a neutral impact on the US Dollar and the EUR/USD pair. Eurozone Inflation: Eurozone inflation could remain stable, around 1.5%, which is close to the ECB's target, providing no clear direction for the EUR/USD pair. US Economic Data: US economic data, such as GDP growth, could come in as expected, providing no surprises and having a neutral impact on the EUR/USD pair. European Commission Economic Forecasts: The European Commission's economic forecasts could be revised slightly, but remain broadly in line with current expectations, providing no clear direction for the EUR/USD pair. German Economic Data: German economic data, such as GDP growth and industrial production, could come in as expected, providing no surprises and having a neutral impact on the EUR/USD pair. These neutral factors could help to stabilize the EUR/USD pair, reducing volatility and making it more challenging to predict the pair's direction. Trading Alert⚠️ : News Releases and Position Management ? ?️ ?? As a reminder, news releases can have a significant impact on market prices and volatility. To minimize potential losses and protect your running positions, we recommend the following: Avoid taking new trades during news releases Use trailing stop-loss orders to protect your running positions and lock in profits Please note that this is a general analysis and not personalized investment advice. It's essential to consider your own risk tolerance and market analysis before making any investment decisions. Keep in mind that these factors can change rapidly, and it's essential to stay up-to-date with market developments and adjust your analysis accordingly. ?Supporting our robbery plan will enable us to effortlessly make and steal money ?? Tell your friends, Colleagues and family to follow, like, and share. Boost the strength of our robbery team. Every day in this market make money with ease by using the Thief Trading Style.???❤️?? I'll see you soon with another heist plan, so stay tuned ?
OANDA:EURCAD is testing a significant resistance zone, marked by historical price rejections and strong supply on the 4H timeframe. Given the overextended move into resistance, we could see a reversal if the price shows clear signs of rejection. Look for bearish confirmation signals such as a pinbar, long upper wicks, or bearish engulfing candles. If sellers regain control at this level, I anticipate a move downward toward the 1.49110 level.
Johnson & Johnson (NYSE: JNJ), one of the global giants in the pharmaceutical, medical device and consumer sectors, is in the spotlight as it prepares to release its fourth-quarter 2024 results. Analysts and the market expect the results to reflect a combination of macroeconomic challenges and strategic opportunities that will define its performance in 2025. Expected Q4 2024 results 1. Pharmaceuticals: The pharmaceutical business remains the key revenue driver for J&J, driven by drugs such as Stelara (treatment for immune diseases) and Darzalex (multiple myeloma). However, the recent loss of exclusivity for some products could affect revenues, especially in key markets such as the United States and Europe. o Expected revenues: Moderate growth of 3-5% year-on-year is projected in the pharmaceutical segment. 2. Medical devices: The post-pandemic recovery has favored this segment, with an increase in surgical procedures and advanced therapies. However, supply chain issues and high material costs could limit gains. 3. Consumer products: The consumer division, now under the Kenvue brand, has experienced stable growth thanks to products such as Tylenol and Neutrogena. However, competition in this market remains intense, which could limit profit margins. Technical analysis with WACD The company is currently in a price correction that began in September 2024 and has moved since December last year in a range between $150 and $142 a share. Currently there have been bearish signals in the WACD indicator in its WVAP signal that show us that it can correct its price again in that range. On the other hand the smoothed triple mean seems to be extending its move from the recent lows, indicating that this signal could be short-lived and could send the price subsequently towards the high end of the range if the expected results are as indicated. Outlook for 2025 1. Pharmaceutical innovation: Johnson & Johnson has strengthened its focus on research and development, with a robust pipeline that includes oncology treatments and advanced gene therapies. Expected new drug approvals could be a key catalyst for long-term growth. 2. Legal Challenges: Litigation related to talc and other consumer products continues to be a source of uncertainty. While J&J has established a compensation fund, legal costs could affect its results in 2025. 3. Digital transformation and sustainability: The company is investing in digital technologies to improve operational efficiency and in sustainability initiatives that align its business model with market and regulatory expectations. Conclusion Johnson & Johnson faces a mixed picture in the near term, with challenges in some key segments and growth opportunities in others. Fourth quarter 2024 results will be crucial in gauging its ability to overcome current pressures and capitalize on its innovation strategy in 2025. With a focus on diversification and innovation, J&J remains a benchmark in the healthcare sector, but its success will depend on how it manages legal and macroeconomic risks in the coming years. Ion Jauregui - ActivTrades Analyst ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acing on the information provided does so at their own risk.
Sell Gold Now at 2728/2733 Tp1 2723 Tp2 2717 TP3 2712 SL 2736
A highly probable expanding triangle has just been formed as the 'B' wave of an expanded flat. The "C' wave should drop to the region of strong support at 74,000 that I see as a good buying opportunity.
Dear friends, what are your thoughts on gold? Overall, gold has seen a significant increase yesterday, with a price rise surpassing the 2720 level. It is currently trading at a new high of 2728, showing strong gains for the day. So what reasons and factors have driven this? Regarding the influencing factors: Safe-haven money flows have strengthened following statements about tariff policies from former President Trump, along with expectations that the Federal Reserve (Fed) will continue to cut interest rates. These factors have put pressure on US Treasury yields, creating positive momentum for gold. However, risks from the mild recovery of the USD and optimistic risk sentiment in the market are somewhat restraining stronger upward momentum. Regarding new prospects for gold: On the H4 chart, according to Joe's personal view, gold is currently receiving strong support at 2620. Breaking below this level would lead to price decreases, while maintaining it would result in price increases. Upon careful observation, it's noteworthy that the Relative Strength Index (RSI) is trending downward in the bullish zone, indicating potential momentum changes and the revival of correction possibilities. If a correction occurs, we cannot rule out the possibility that gold will utilize short-term momentum to test the area of interest at the upper boundary within the bullish channel, from which a decline may occur. Best regards, Joegoldwave!
Short Analysis of the GBP/USD Chart: - *Current Price*: 1.22722 USD per GBP. - *Resistance Level*: Around 1.23500 USD, marked as a rejection zone. - *Support Trendline*: An upward trendline connecting the lows from January 10 to January 21. - *Potential Movement*: Indication of a downward movement from the rejection zone, suggesting a bearish outlook. target based on the provided GBP/USD chart analysis: Bearish Scenario: - *Initial Target*: If the price rejects the resistance level around 1.23500 USD and confirms a downward movement, the initial target would be around 1.22000 USD. - *Extended Target*: If the bearish trend continues, a more extended target could be around 1.21000 USD, close to the next significant support level.